We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Celadon Pharmaceuticals Plc | CEL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -2.50 | -2.38% | 102.50 | 12:04:35 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 105.00 | 102.50 | 105.00 | 102.50 | 105.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 16/11/2023 16:18 by czar Take a look back at GW Pharma they were a penny stock on AIM that followed the same path as Celadon and sold for $7.2b $220 a share. CEL will emulate GW, maybe not $220 a share but many many times the current price IMHO. |
Posted at 16/11/2023 10:04 by jaknife Ahhh Luke Warm,It's not a particularly great name to be associated with. I'm expecting a standard equity fund raise at some point, whereupon the convertible will be converted. I assume that GIS are already selling short. czar, "There are a lot of small caps with absurd valuations and Celadon should be many times the current price IMHO." The problem is that CEL's valuation is absurdly high rather than absurdly low. At 102.5p it's a £64m market cap but the interims: show a company with just £3m of net equity of which £1.6m of that is cash and it burnt £3.5m of cash in the last six months! It's an obvious dog! JakNife |
Posted at 16/11/2023 07:33 by ahhh luke warm London, 16 November 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, announces that it has entered into a contract for the commercial supply of its pharmaceutical-grade cannabis product with a leading European medicinal cannabis company.The contract has the potential to generate revenue to Celadon of up to GBP26 million of product (GBP8.7 million annually) over the three year term, with the first delivery anticipated in H2 2024. The two parties retain the option to extend the contract for a further two years by mutual agreement.This latest sales contract follows the two previous UK contracts announced in May and September 2023 respectively. |
Posted at 05/9/2023 19:07 by jaknife No comment on todays RNS?Am I the only person interested in CEL? JakNife |
Posted at 05/6/2023 12:22 by jaknife Any comments on today's finals?* Pitifully small revenue of just £24k & cost of sales of £90k * Hence every £1,000 of product sold cost the company £3,750 to make! * material operating costs giving an overall operating loss of £5.4m! * Other astronomical costs making a total loss before tax of £18.1m! * Cash as at 31 Dec 2022 of £5.1m * But cash as at 31 May 2023 of just £1.8m so cash burn in the first five months of the year is £3.3m, equal to £0.66m a month * net assets at year-end of just £7.0m, which must be c. £3.7m at 31 May * All of this for a bargain market cap of £100m - more than 25 times net assets * Alternatively put, the share price needs to fall 96% to get close to net assets Is Celadon the easiest and most obvious short on AIM? JakNife |
Posted at 11/4/2023 08:20 by czar saint I think the point with this stock is it should never have gone below the placing price of 165p. This all came about because Cannacord reversed Celadon into a shell which was established to take a software business in. As soon as they listed the shareholders in the shell sold out and destroyed the share price. Celadon have made very significant progress and are now the only UK based company with the licence to grow and sell medical grade cannabis in the UK and one of only 11 worldwide. The potential is huge. The James Short interview is worth a listen if you haven't heard it. |
Posted at 16/3/2023 10:01 by czar There clearly are very few private investors involved in CEL, several are using this thread to promote other stocks but none of these have the Home Office Licence. The truth is only a handful of companies worldwide can supply medical-grade cannabis to the pharmaceutical industry, this is an extremely valuable Company IMHO. Celadon will almost certainly receive a take over approach, its a question of WHEN not IF. The big question is at what level a bid will come in at and what would the management accept? GW Pharma gives a great clue as to the sort of number we can expect." -- Receipt of updated Home Office licence enables Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product -- GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredient ("API") since the legalisation of medical cannabis in 2018 -- GMP registration and a Home Office licence are required in order to sell high-THC medicinal cannabis in the UK -- Celadon becomes one of a small number of companies globally with the capability to produce an EU-GMP grade high-THC cannabinoid API" |
Posted at 14/3/2023 15:42 by oakridge Some thoughts on CEL and HELD (from the HELD thread) below.(Don't forget CEL possibly need a cash injection so don't get greedy on the spike!) Oakridge14 Mar '23 - 15:20 - 480 of 481 Edit 0 1 0 News out at CEL. Great news for the cannabis space. What we can say is that CEL, or, those involved in the work around this RNS = a leaky ship! Including that big volume spike / buy a few weeks ago. Naughty! Oakridge14 Mar '23 - 15:40 - 481 of 481 Edit 0 0 0 It's important to watch the reaction at CEL, and particularly the rocket that has been put under the companies share price over recent days. The home office has now extended their license so that they can enter into commercial (non research) agreements to sell a high THC content product to third parties and are the first UK based pharmaceutical facility / cultivators in the UK to do this. They say: "Within the UK, patients prescribed medicinal cannabis are reliant on imported product, often facing lengthy delays and high costs, and by becoming a UK-based producer, Celadon is in a prime position to alleviate the issues currently faced by patients." Well, it's going to be interesting to see what price-point CEL can come in at and maintain. They've already announced that expansion into their second growing room had to delayed this year by spiralling costs we have all grown so familiar with. Their facilities are, I think, only around 10% of HELD's entire license. I'll check on that. So, whilst they may be first over the line and should be congratulated, the scale of their operations, at present, is a fraction of what HELD have been granted in Greece. CEL are also operating from a country with considerably higher costs. Current mkt cap: £265M HELD: c.£11M. HELD still have work to do, but should, all being well, be rubber stamped and selling product at around the end of Q2. AIMO ADYOR |
Posted at 14/3/2023 09:05 by oakridge The rise has been on fairly light volume czar....but then CEL has relatively few shares in issue. There could be any number of reasons why this has rallied recently. Several other cannabis stocks are coming off oversold lows (they all faced a woeful 2022 - a 'hangover' if you like - after all the initial (and slightly premature) enthusiasm of the sector in the previous year(s).Re. CEL specifically, there could be upcoming clinical findings to report, expansion to their license, or perhaps another raise on the way (check their cash balance and burn rates). Hellenic Dynamics (HELD) will be moving up at some point imho. As a wholesaler to licensed distributors, they have already signed term sheets into the German market with first sales anticipated in late Q2. Unlike CEL and other UK firms such as Ananda, HELD's license is to grow for the purposes of full commercial sales....not just research. It also has amongst the largest license ever granted in Europe.....growing out of an ex UN facility in Northern Greece, with a compelling cost-base. They have taken on ex Avida Global staff.....who have done it all before in latin America. It's a company to watch in 2023 - 2024 imo. NAI and ADYOR. |
Posted at 15/1/2023 09:34 by czar Wow this interesting little Company is certainly flying under the radar!!!Based on the above, Celadon remains confident that the Company will obtain registration from the MHRA for the GMP manufacturing of its cannabis API. The directors anticipate receiving this registration during Q1 2023. James Short, CEO of Celadon, commented: "The Company is pleased to confirm that the inspection from the MHRA and third-party testing of the batches of Celadon's cannabis oil have now been completed in line with management expectations. We remain confident that the Company will obtain registration from the MHRA for the GMP manufacturing of its cannabis API during Q1 2023, following which we believe we will be one of a limited number of GMP approved pharmaceutical cannabis facilities in the world. This will be a significant milestone for the Company and will unlock significant revenue opportunities." If this registration comes through this quarter CEL will fly and should be above the placing price by the end of this year. Its very strange to find a Company with such potential completely ignored. Fingers crossed. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
